SCHEMBL10043877

SCHEMBL10043877

Cc1cc2c(cn1)cc(-c1cc(NC(=O)NC(=O)c3ccco3)ccc1C)c(=O)n2C

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 11/20 0.45
NPC1 O15118 8/20 0.45
SMN1; SMN2 Q16637 6/20 0.43
TP53 P04637 4/20 0.43
PKM P14618 2/20 0.43
PYGM P11217 1/20 0.42
ALDH1A1 P00352 6/20 0.42
KMT2A Q03164 5/20 0.42
MEN1 O00255 4/20 0.42
SYK P43405 1/20 0.41
MAPT P10636 3/20 0.40
KDM4E B2RXH2 2/20 0.40
HPGD P15428 2/20 0.40
POLB P06746 1/20 0.40
HTT P42858 1/20 0.39
HSD17B10 Q99714 1/20 0.38
MAPK14 Q16539 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043850 0.86 SYK (0.50) RAB9ANPC1SMN1; SMN2ALDH1A1KMT2A
SCHEMBL10043864 0.85 SYK (0.44) RAB9ANPC1TP53KMT2AMEN1
SCHEMBL10043857 0.85 POLB (0.45) RAB9ANPC1SMN1; SMN2TP53ALDH1A1
SCHEMBL14011580 0.83 RAB9A (0.50) RAB9ANPC1SMN1; SMN2TP53PKM
SCHEMBL10043870 0.83 RAB9A (0.40) RAB9ANPC1SMN1; SMN2TP53ALDH1A1
SCHEMBL10043853 0.83 SYK (0.48) RAB9ANPC1TP53PKMALDH1A1
SCHEMBL10043854 0.83 KDR (0.45) SYK
SCHEMBL10043874 0.83 SYK (0.39) RAB9ANPC1SMN1; SMN2TP53PKM
SCHEMBL10043876 0.83 RAB9A (0.42) RAB9ANPC1SMN1; SMN2ALDH1A1KMT2A
SCHEMBL10043821 0.82 SYK (0.49) RAB9ANPC1SMN1; SMN2TP53KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC RAB9A 1818/4885NPC1 4095/4885SMN1; SMN2 2302/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC RAB9A 1818/4885NPC1 4095/4885SMN1; SMN2 2302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.